By Paul ZiobroIllumina expects sales to decline and a wider loss this year as conditions remain challenging for the gene-sequencing company. The San Diego-based firm on Thursday said that it now expects total revenue to decline between 2% and 3% this year, compared with prior projections for growth of about 1%.

Source: Wall Street Journal November 10, 2023 09:40 UTC